Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.

Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01206-17. doi: 10.1128/AAC.01206-17. Print 2017 Nov.

2.

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.

Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P, Wakeland E, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00751-17. doi: 10.1128/AAC.00751-17. Print 2017 Aug.

3.

Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations.

Hall RG 2nd, Pasipanodya JG, Swancutt MA, Meek C, Leff R, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):552-559. doi: 10.1002/psp4.12208. Epub 2017 Jul 13.

4.

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ.

Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158.

5.

Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.

Hall RG Nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):674-681. doi: 10.1002/psp4.12146. Epub 2016 Nov 21.

6.

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.

Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S95-S101.

7.

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.

Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S88-S94.

8.

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.

Deshpande D, Srivastava S, Pasipanodya JG, Bush SJ, Nuermberger E, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S80-S87.

9.

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.

Srivastava S, Deshpande D, Pasipanodya JG, Thomas T, Swaminathan S, Nuermberger E, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S75-S79.

10.

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.

Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D, Nuermberger E, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S63-S74.

11.

The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism.

Rogers Z, Hiruy H, Pasipanodya JG, Mbowane C, Adamson J, Ngotho L, Karim F, Jeena P, Bishai W, Gumbo T.

EBioMedicine. 2016 Sep;11:118-126. doi: 10.1016/j.ebiom.2016.07.031. Epub 2016 Jul 27.

12.

Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.

Modongo C, Pasipanodya JG, Magazi BT, Srivastava S, Zetola NM, Williams SM, Sirugo G, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5928-32. doi: 10.1128/AAC.00962-16. Print 2016 Oct.

13.

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. doi: 10.1128/AAC.00990-16. Print 2016 Oct.

14.

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.

Srivastava S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5922-7. doi: 10.1128/AAC.00961-16. Print 2016 Oct.

15.

Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.

Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, Peloquin CA, Bisson GP, Vinnard C.

BMC Infect Dis. 2016 Jun 1;16:242. doi: 10.1186/s12879-016-1576-1.

16.

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.

Srivastava S, Pasipanodya JG, Ramachandran G, Deshpande D, Shuford S, Crosswell HE, Cirrincione KN, Sherman CM, Swaminathan S, Gumbo T.

EBioMedicine. 2016 Apr;6:126-138. doi: 10.1016/j.ebiom.2016.02.040. Epub 2016 Feb 27.

17.

Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 May 23;60(6):3779-85. doi: 10.1128/AAC.02821-15. Print 2016 Jun.

18.

Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2895-900. doi: 10.1128/AAC.03112-15. Print 2016 May.

19.

Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality.

Pasipanodya JG, Mubanga M, Ntsekhe M, Pandie S, Magazi BT, Gumedze F, Myer L, Gumbo T, Mayosi BM.

EBioMedicine. 2015 Sep 21;2(11):1634-9. doi: 10.1016/j.ebiom.2015.09.034. eCollection 2015 Nov.

20.

Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease.

Deshpande D, Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2157-63. doi: 10.1128/AAC.02854-15. Print 2016 Apr.

Supplemental Content

Loading ...
Support Center